AVLNAvalyn Pharma Inc.
$25.70
$25.70
$25.3752 weeks$39.39
AVLN in its own filings
Nothing in AVLN's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
8
Events found in the filings · across 63 filings · the record starts in 2026
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 16, 2026
Most recent filing · Form 8-K
- Record starts
- May 1, 2026
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 11, 2026
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 16, 2026Appointment of Director On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Avalyn Pharma Inc. (the “Company”), the Board appointed Robert Meyer, M.D. to the Board as a Class II director for an initial …Director or officer change · Form 8-K
- Aug 12, 2026Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- Jul 1, 2026On June 29, 2026 (the “Effective Date”), Avalyn Pharma Inc. (the “Company”) entered into a First Amendment to the Sublease (the “Sublease Amendment”), which amends that certain Sublease Agreement (the “Sublease Agreement”) with CRISPR Therapeutics, Inc. (the “Sublandlord”), dated as of August 29, 2025, providing for …Material agreement entered · Form 8-K
- Jun 3, 2026Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- May 1, 2026Amendments to Articles of Incorporation or Bylaws As previously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-294932) (the “Registration Statement”) of Avalyn Pharma Inc. (the “Company”) and in connection with the consummation of the initial public offering of the Company’s common stock …Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Stocks with no debt
Biotechnology
The closest names by size in the same industry